EGFR is overexpressed in nearly 60% of glioblastoma tumors, often the consequence of gene amplification (in 40% of these tumors) or the common EGFRvIII deletion (in 25% of these tumors), and it is considered a poor prognostic factor. The gene discussed is EGFR; the disease is glioblastoma.